1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Biotest AG

Biotest AG

BIO3.DE
Biotest AGDE flagDeutsche Börse
32.20
EUR
-0.20
- -
1.58BMarket Cap

Total Valuation

Biotest AG carries a market capitalization of 1.58B, placing it among publicly traded companies globally. Its enterprise value stands at 1.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.58B
Enterprise Value1.11B

Share Statistics

Biotest AG currently has 39.57M shares outstanding.

Shares Outstanding39.57M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Biotest AG trades at a trailing price-to-earnings ratio of 46.53. The price-to-sales ratio is 1.85, and the price-to-book ratio stands at 4.00.

PE Ratio46.53
PS Ratio1.85
PB Ratio4.00
P/TBV Ratio2.38
P/FCF Ratio81.46
P/OCF Ratio81.46

Enterprise Valuation

On an enterprise value basis, Biotest AG trades at an EV/EBITDA multiple of 102.13 and an EV/FCF ratio of 24.26. The EV/Sales ratio of 1.75 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 102.13 provides insight into valuation relative to core operating earnings.

EV / Sales1.75
EV / EBITDA102.13
EV / EBIT102.13
EV / FCF24.26

Financial Position

Biotest AG maintains a current ratio of 4.93, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities.

Current Ratio4.93
Quick Ratio0.37
Debt / EquityN/A
Debt / EBITDAN/A
Interest Coverage0.33

Financial Efficiency

Return on Equity (ROE)-8.15
Return on Assets (ROA)-1.71
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)34.21
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.01

Taxes

Over the trailing twelve months, Biotest AG has paid -1.10M in income taxes, reflecting an effective tax rate of 323.93.

Income Tax-1.10M
Effective Tax Rate323.93

Stock Price Statistics

Biotest AG's stock has gained approximately 7.33333% over the past 52 weeks. The 50-day moving average sits at 29.96, while the 200-day moving average is 28.23.

Beta (5Y)N/A
52-Week Price Change7.33333%
50-Day Moving Average29.96
200-Day Moving Average28.23
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Biotest AG generated 635.20M in revenue and converted that into -24.50M in net income, yielding earnings per share of -0.63. EBITDA reached 10.90M, while operating income came in at 10.90M.

Revenue635.20M
Gross Profit147.30M
Operating Income10.90M
Pretax Income-25.70M
Net Income-24.50M
EBITDA10.90M
EBIT10.90M
Earnings Per Share (EPS)-0.63

Balance Sheet

Total book value stands at 292.90M, with working capital of 628.60M providing operational flexibility.

Cash & Cash Equivalents59.80M
Total DebtN/A
Net Debt-41.80M
Equity (Book Value)292.90M
Book Value Per Share7.54
Working Capital628.60M

Cash Flow

Biotest AG produced 14.40M in operating cash flow over the past twelve months.

Operating Cash Flow14.40M
Capital ExpendituresN/A
Free Cash Flow14.40M
FCF Per Share0.37

Margins

Biotest AG operates with a gross margin of 23.19, reflecting its pricing power and cost economics. The operating margin of 1.72 and net profit margin of -3.86 provide insight into operational efficiency.

Gross Margin23.19
Operating Margin1.72
Pretax Margin-4.05
Profit Margin-3.86
EBITDA Margin1.72

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield3.44
FCF Yield1.23

Stock Splits

Biotest AG's most recent stock split took place on July 15, 2015 with a 1:3 split ratio.

Last Split Date7/15/2015
Split Ratio1:3

Scores

Biotest AG posts an Altman Z-Score of 2.05, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.05